Brief: Palvella Therapeutics Completes Enrollment In Phase 3 Selva Trial Of Qtorin™ Rapamycin For Microcystic Lymphatic Malformations, Exceeding Enrollment Target By Over 25%
23/06/2025 12:40
June 23 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 3 SELVA TRIAL OF QTORIN™ RAPAMYCIN FOR MICROCYSTIC LYMPHATIC MALFORMATIONS, EXCEEDING ENROLLMENT TARGET BY OVER 25% PALVELLA THERAPEUTICS INC - TOP-LINE DATA EXPECTED IN Q1 2026 Source text: ID:nGNX3QLmt2 Further company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs